东亚药业
(605177)
| 流通市值：20.74亿 | | | 总市值：21.14亿 |
| 流通股本：1.13亿 | | | 总股本：1.15亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 190,921,213.83 | 1,198,238,535.39 | 963,019,242.47 | 648,226,520.15 |
| 营业收入 | 190,921,213.83 | 1,198,238,535.39 | 963,019,242.47 | 648,226,520.15 |
| 二、营业总成本 | 193,939,111.07 | 1,173,707,357.93 | 914,079,555.24 | 614,661,764.74 |
| 营业成本 | 123,394,635.74 | 865,663,163.87 | 703,230,309.84 | 480,912,437 |
| 税金及附加 | 2,437,450.15 | 11,362,718.63 | 8,539,592.24 | 4,444,363.27 |
| 销售费用 | 1,759,543.49 | 15,387,268.47 | 10,982,915.66 | 7,731,959.02 |
| 管理费用 | 43,208,414.35 | 170,269,093.67 | 127,438,407.37 | 80,124,809.87 |
| 研发费用 | 23,009,005.87 | 117,016,684.56 | 67,140,483.98 | 43,529,401.21 |
| 财务费用 | 130,061.47 | -5,991,571.27 | -3,252,153.85 | -2,081,205.63 |
| 其中:利息费用 | 1,936,606.19 | 2,039,662.8 | 2,478,028.51 | 1,279,456.7 |
| 其中:利息收入 | 1,306,491.43 | 5,674,745.08 | 4,289,818.64 | 2,163,246.03 |
| 加:投资收益 | 737,521.13 | 3,943,815.78 | 3,342,771.63 | 2,870,424.43 |
| 资产处置收益 | -5,963.93 | -3,130,864 | -90,624.45 | -51,637.15 |
| 资产减值损失(新) | -12,629,703.08 | -144,052,482.6 | -3,552,573.56 | -2,570,631.01 |
| 信用减值损失(新) | 3,330,066.74 | -1,179,208.39 | -3,315,686.94 | -2,058,717.13 |
| 其他收益 | 3,955,914.04 | 18,154,530.35 | 14,544,601.08 | 10,550,336.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,630,062.34 | -101,733,031.4 | 59,868,174.99 | 42,304,530.57 |
| 加:营业外收入 | 76,004.56 | 526,138.61 | 30,148 | 30,148 |
| 减:营业外支出 | 84,964.95 | 16,965,194.78 | 4,445,608.27 | 3,167,895.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -7,639,022.73 | -118,172,087.57 | 55,452,714.72 | 39,166,782.61 |
| 减:所得税费用 | -694,118.56 | -17,472,628.07 | 10,296,716.32 | 6,701,969.59 |
| 六、净利润 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 | 32,464,813.02 |
| 持续经营净利润 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 | 32,464,813.02 |
| 归属于母公司股东的净利润 | -6,919,576.54 | -100,660,051.84 | 45,169,152.65 | 32,473,045.75 |
| 少数股东损益 | -25,327.63 | -39,407.66 | -13,154.25 | -8,232.73 |
| (一)基本每股收益 | -0.06 | -0.9 | 0.4 | 0.29 |
| (二)稀释每股收益 | -0.05 | -0.69 | 0.31 | 0.22 |
| 九、综合收益总额 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 | 32,464,813.02 |
| 归属于母公司股东的综合收益总额 | -6,919,576.54 | -100,660,051.84 | 45,169,152.65 | 32,473,045.75 |
| 归属于少数股东的综合收益总额 | -25,327.63 | -39,407.66 | -13,154.25 | -8,232.73 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |